Also found in: Dictionary, Thesaurus, Wikipedia.


a nonnucleoside human immunodeficiency virus-1 (HIV-1) reverse transcriptase inhibitor that acts by interfering with the ability of the virus to replicate; used in combination with other antiretroviral agents in treatment of HIV-1 infection, administered orally.


Viramune, Viramune XR

Pharmacologic class: Nonnucleoside reverse transcriptase inhibitor

Therapeutic class: Antiretroviral

Pregnancy risk category C

FDA Box Warning

Drug has caused severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in first 18 weeks. In some cases, patients had nonspecific, prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are commonly associated with rash. Women and patients with higher CD4+ cell counts at initiation of therapy are at increased risk. Women with CD4+ cell counts greater than 250/mm3, including pregnant women receiving nevirapine in combination with other antiretrovirals for treatment of HIV-1 infection, are at greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both men and women, and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for postexposure prophylaxis (PEP). Use of nevirapine for occupational and nonoccupational PEP is contraindicated. Patients must discontinue drug and seek immediate medical help if they develop hepatitis signs or symptoms or have increased transaminase levels along with rash or other systemic symptoms.

Severe, life-threatening skin reactions (including fatal cases) have occurred; these have included Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions. Patients who develop signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue drug and seek immediate medical help.

Monitor patients intensively during first 18 weeks of therapy. Be especially vigilant during first 6 weeks. Don't restart drug in patient who has had clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms, or after severe rash, or hypersensitivity reaction.


Inhibits human immunodeficiency virus (HIV) nonnucleoside reverse transcriptase by binding directly to reverse transcriptase and blocking RNA-dependent and DNA-dependent polymerase activity


Oral suspension: 50 mg/5 ml

Tablets: 200 mg

Tablets (extended-release): 400 mg

Indications and dosages

Treatment of HIV-1 infection

Adults: 200 mg P.O. daily for 14 days, then 200 mg (immediate-release) P.O. b.i.d., given in combination with other antiretrovirals; 400 mg (extended-release) P.O. daily after either a 14-day 200-mg lead-in regimen or after switching from a 200-mg b.i.d. regimen.

Children ages 15 days and older: 150 mg/m2 (immediate-release tablet or oral suspension) P.O. once daily for 14 days, followed by 150 mg/m2 b.i.d. thereafter. Total daily dosage shouldn't exceed 400 mg for any patient.

Dosage adjustment

• Chronic hemodialysis

Off-label uses

• Prophylaxis of maternal-fetal HIV transmission


• Hypersensitivity to drug or its components

• Moderate or severe hepatic impairment (Child-Pugh Class B or C, respectively)

• Use as part of occupational and nonoccupational postexposure prophylaxis regimens


Use cautiously in:

• impaired renal or hepatic function

• pregnant or breastfeeding patients

• children.


• Be aware that drug should be given alone for first 14 days to reduce incidence of rash.

• If patient experiences rash during 14-day lead-in period with immediate-release form, don't initiate extended-release form until rash has resolved.

• Don't continue immediate-release lead-in dosing regimen beyond

28 days. If immediate-release dosing is interrupted for more than 7 days, restart recommended dosing, including 14-day lead-in dosing.

• For patients who interrupt extended-release dosing for more than 7 days, restart recommended lead-in dosing with immediate-release form using one 200-mg tablet daily for first 14 days.

• Be aware that drug shouldn't be started in adult females with CD4+ cell counts greater than 250/mm3 or in adult males with CD4+ cell counts greater than 400/mm3 because of serious and life-threatening hepatotoxicity, unless benefit outweighs risk.

• Give with or without food.

Adverse reactions

CNS: paresthesia, headache, malaise, fatigue

GI: nausea, diarrhea, abdominal pain

Hematologic: agranulocytosis

Hepatic: hepatitis, hepatotoxicity, hepatic failure

Musculoskeletal: myalgia, pain

Skin: rash, blistering, toxic epidermal necrolysis, Stevens-Johnson syndrome

Other: fever


Drug-drug. Antiarrhythmics, antifungals, calcium channel blockers, cancer chemotherapy, ergot alkaloids, immunosuppressants, motility agents, opiate agonists: possible decreased plasma concentrations of these drugs

Anticoagulants: possible increased or decreased anticoagulant plasma concentrations

Clarithromycin, efavirenz, indinavir, ketoconazole, methadone: decreased activity of these drugs

Ethinyl estradiol, norethindrone: decreased contraceptive plasma levels Fluconazole: increased nevirapine level Lopinavir/ritonavir: decreased lopinavir activity

Nelfinavir: decreased nelfinavir active metabolite, minimum nelfinavir concentration

Rifabutin: increased rifabutin level

Drug-diagnostic tests. Alanine amino-transferase, aspartate aminotransferase, bilirubin, gamma-glutamyltransferase: increased levels

Hemoglobin, neutrophils: decreased levels

Drug-herbs. St. John's wort: decreased nevirapine blood level

Patient monitoring

Check closely for rash (which may be first sign of Stevens-Johnson syndrome), especially during first 6 months of therapy.

• Monitor patient's weight, temperature, and chest X-ray periodically.

• Assess patient's appetite and energy and physical activity levels.

• Monitor liver function tests and CBC with white cell differential.

Patient teaching

• Tell patient he may take with or without food.

• Tell patient or caregiver to shake suspension gently before use and that it's important to take the entire measured dose of suspension by using an oral dosing syringe or dosing cup.

• Tell patient or caregiver that the extended-release tablet must be swallowed whole and must not be chewed, crushed, or divided.

• Instruct patient to take missed dose as soon as he remembers. But if it's almost time for next dose, tell him to skip missed dose. Caution him not to double the dose.

• Inform female patient that hormonal contraceptives, implants, or shots may be ineffective during nevirapine therapy. Urge her to use alternative birth-control method.

Teach patient to recognize and immediately report rash, easy bruising or bleeding, and signs and symptoms of hepatotoxicity.

• Inform patient that nevirapine won't cure HIV or prevent its transmission.

• Caution female not to breastfeed, because breast milk may transfer HIV to infant.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.


/ne·vir·a·pine/ (nĕ-vir´ah-pēn) a nonnucleoside inhibitor of HIV-1reverse transcriptase, used in combination with other antiretroviral agents in the treatment of HIV infection.


(nə-vîr′ə-pēn′, -pĭn)
An antiviral drug, C15H14N4O, that is a non-nucleoside reverse transcriptase inhibitor and is used in combination with other drugs for the treatment of HIV infection.


an antiretroviral nonnucleoside reverse transcriptase inhibitor.
indication It is prescribed in combination for the treatment of human immunodeficiency virus infection.
contraindications It should not be given to patients with an allergy or sensitivity to the medication or to patients taking ketoconazole or oral contraceptives. When used alone, there is rapid and uniform appearance of viral resistance.
adverse effects The side effects most often reported include headache, rash, drug fever, and diarrhea.


Viramune® AIDS An antiretroviral non-nucleoside reverse transcriptase inhibitor, combined with nucleoside RTIs to manage HIV infection Adverse effects Rash. See Nonnucleoside reverse transcriptase inhibitor, TIBO. Cf Antiretroviral agent, Delavirdine.


A non-nucleoside reverse transcription inhibitor drug used in combination with other antiretroviral drugs to treat HIV infections. The drug is on the WHO official list. A brand name is Viramune.
References in periodicals archive ?
13] In this study, zidovudine + lamivudine + nevirapine based combination was prescribed in majority of the patients and zidovudine being a myelosuppressive drug is known to cause anemia within 3 months of initiating therapy.
Nevirapine Extended-release Tablets, 100 mg, had US sales of approximately USD67,000 for the 12 months ending 30 Sept 2015, according to IMS Health.
During the delivery of seropositive pregnant woman, a single dose regime of nevirapine 200 mg tablet is given at the time of onset of labour and nevirapine syrup 2mg/kg of body weight is offered to the babies within 72 hrs of birth.
On day 3 after admission, he was prescribed 300 mg zidovudine twice daily, 150 mg lamivudine twice daily and 200 mg nevirapine daily.
Policy makers can now make informed decisions regarding the WHO 2010 prevention of mother-to-child transmission (PMTCT) guidelines and the combined use of nevirapine and co-trimoxazole prophylaxis for extended periods of time.
The clinics followed NACO guidelines for PPTCT and administered a single dose of nevirapine to the mother at the time of delivery and one dose to the infant within 72 h after birth.
10) The new guidelines provide HAART to all pregnant women with CD4 cell counts [less than or equal to] 350 cells/[micro]l, dual prophylaxis from 14 weeks of pregnancy, nevirapine and tenofovir/emtricitabine as tail cover, and either 6 weeks' nevirapine prophylaxis to infants of mothers on HAART or to non-breastfeeding HIV-exposed infants or continued nevirapine prophylaxis for breastfeeding HIV-exposed infants until 1 week after breastfeeding stops.
In this effort, the investigators hoped to determine if the antiretroviral drug nevirapine, manufactured by Boehringer, administered to HIV-positive mothers and their babies after birth could prevent transmission of the virus.
VERxVE is a pivotal trial that compared the frequently prescribed lipid-friendly* antiretroviral ViramuneEeA IR with once daily nevirapine (ViramuneEeA XR.
Interestingly, hepatotoxicity to either efavirenz or nevirapine appears not to increase the risk on exposure to the alternative NNRTI [38,39].
These enzyme-inducing ARV drugs include non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine and protease inhibitors such as ritonavir.
Nevirapine is an important antiretroviral agent in the prevention of mother-to-child transmission of HIV.